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This paper reviews the current knowledge of the molecular aspects of mucosal
repair.
The mucosal lining of the gut, and epithelial cells in particular, undergo constant
renewal. New cells are created from precursors in the proliferative zone, and, under the
influence of "growth factors," they then undergo maturation and differentiation over the
course of around a week as they move toward the lumen. Here they are lost, not by pas-
sive cell shedding into the lumen, but by an active process ofcell death termed apoptosis,
which may be considered the ultimate terminal differentiation event. In the mucosa ofthe
stomach, cells also move downward, at a much slower rate, from the proliferative zone at
the base of the gastric pits, down into the glands. This constant and rapid turnover of the
gastrointestinal mucosa is, therefore, well suited to the prompt restoration of mucosal
integrity following damage. The speakers in this session presented experimental evidence
for how this may be achieved. In the discussion that ensued, the main issues were, first,
the relative importance of the many factors at play in ulcer healing: is there a molecular
"holy grail"? and second, the clinical relevance ofthe molecular events to the pathophys-
iology and treatment ofclinically important mucosal defects.
Three main healing events occur following the experimental creation ofan ulcer. The
first is a rapid phase of epithelial restitution during which existing viable epithelial cells
at the ulcer edge migrate inward to close the gap. Second, over the next few days, new
cells are formed by proliferation to repopulate the mucosal breach. And third, new matrix
is laiddown, inflammatory cells are replaced by non-epithelial cells in the laminapropria,
and this remodeling is accompanied by angiogenesis, the growth offeeding blood vessels
[1]. Of course, in vivo, these events do not occur in this stepwise fashion, particularly
when aggressive factors such as Helicobacter pylori are present, but nevertheless this
model does provide a conceptual framework on which to place the processes of mucosal
repair.
The details of the process of restitution were addressed by the first two speakers in
this session. Basson presented evidence from a cell culture model ofmucosal damage that
the migrating epithelial cells are notmerely undifferentiated and immature "foot soldiers"
but instead have a specialized and polarized phenotype, uniquely adapted to movement.
However, acquisition of a specialized migratory phenotype was not necessarily accompa-
nied by loss ofbrush border enzyme expression (a marker ofthe differentiated phenotype
in these Caco2 small-intestinal-like cells). In his system, a variety offactors including the
extracellular matrix, peptides and the more classical growth factors were shown to induce
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the differentiation of this migratory phenotype to varying degrees. In vivo, multiple fac-
tors are released so that the restituting cell population is probably heterogeneous.
Interestingly, and of possible therapeutic importance, factors differed in the extent to
which they induced the migratory phenotype, and this was not always linked to dediffer-
entiation. The ideal therapeutic agent may, therefore, be one that promotes migration but
yet leaves the intact, healed epithelium relatively differentiated. Although the cells in this
model were originally derived from a colon cancer line and have many ofthe characteris-
tics of small intestinal epithelial cells, there is no reason not to apply these ideas to ulcer
healing elsewhere in the gut.
Lacy presented further insights into how rapid epithelial restitution may be modulat-
ed. In the mouse stomach, he found that a chronic and repetitive hyperosmolar insult ulti-
mately led to an acceleration of restitution compared with the "unconditioned" mucosa
and that this adaptive response was accompanied by a widening ofthe proliferative zone.
Several other intriguing changes in the cell populations within the gastric pits and glands
were observed: chronic hyperosmolar insult led to a decrease in parietal and gastrin-
secreting (G) cells and a tendency to increased somatostatin-secreting (D) cell number. In
addition, a new population of"vesiculated" cells, with some features ofimmature mucous
neck cells by electron microscopy, appeared in the lower third of the gastric gland, in an
area previously populated by parietal cells. What is the function of this new population?
Lacy and others thought that these vesiculated cells may represent a distinct lineage and
were not precursor cells, despite their proximity to the proliferative zone. Indeed, it is
tempting to speculate that these cells may be ideally located to promote proliferation and
healing, through the local secretion ofmucosal repair proteins. It would also explain how
chronic superficial injury ultimately leads to a more rapid restitutive response.
What is the role ofthe neuroendocrine cells in enhancing the mucosal repair process?
No clearpicture emerged. On a simplistic level, gastrin stimulates gastric mucosal growth
while somatostatin inhibits it, so that the lack ofsomatostatin receptors at the edge ofheal-
ing ulcers may represent an appropriate response to aid mucosal repair [2]. If gastrin and
somatostatin control mucosal growth, do acid-inhibitory drugs heal ulcers through
increasing circulating gastrin? This possibility, that it is increasing circulating gastrin con-
centrations rather than acid inhibition which stimulates ulcer healing, was considered
unlikely. In rats, experimental ulcers can be healed with acid suppression induced by giv-
ing a potent antagonist ofthe gastrin/CCKB receptor [3], an agent thatproduces acid inhi-
bition yet blocks the trophic effect of gastrin on the gastric mucosa. Interestingly, in
Lacy's model there was an increased D:G cell ratio accompanying increased epithelial
proliferation, which is at variance with the generally-accepted wisdom that circulating
gastrin is trophic to the gastric mucosa. It also differs from the situation in human chron-
ic gastritis due to H. pylori, where there is increased proliferation yet a decreased D:G
ratio. Exploring the role ofthese gastric peptides in vivo is an area ofpotential importance,
both in order to understand the processes of mucosal repair and in terms of the potential
for therapy. Obviously, gastrin and somatostatin are not the only growth stimulatory and
inhibitory molecules in the gastric mucosa.
Which molecules are the most important players in mucosal repair? This is likely to
depend partly upon which part of the gut is injured and the nature of the injury. Playford
has recently classified several of the key mucosal repair peptides according to their func-
tion [4]. In this classification, epidermal growth factor, which is capable of performing
many ofthe functions essential for good repair, is considered an example ofa luminal sur-
veillance peptide.Although continually secreted into the lumen, it is only able to bind to its
receptor, located on the basolateral surface ofthe epithelial cell, when mucosal integrity is
breached. On the otherhand, pancreatic secretory trypsin inhibitor and transforming growth
factor-a are considered mucosal integrity peptides, ensuring normal barrier function. TheMoss and Wright: Molecular aspects ofmucosal repair: a summary
third group, the trefoil factors, appear to act as rapid response molecules, upregulated at
times of injury. Of particular relevance to the healing process is a distinct glandular con-
stituent - the ulcer associated cell lineage - which produces several repair peptides
including trefoil peptides and epidermal growth factor as well as mucus. It has, therefore,
been suggested that these cells act as a "first aid kit," pouring healing agents onto the ulcer
base. The ulcer-associated lineage is present only at the site ofchronic mucosal injury and
probably arises from the duct region of metaplastic epithelium, such as intestinal metapla-
sia in the stomach. Might these be related to the vesiculated cells ofLacy's mice?
Exactly what the trefoils do in ulcer healing is unclear. Currently, this is difficult to
study in vivo because the recombinant proteins are so expensive to produce. Pretreating
rats with human spasmolytic polypeptide causes a moderate reduction in indomethacin-
induced gastric damage, less impressive than similar doses ofepidermal growth factor [5].
It would be interesting to examine whether they are beneficial if given after the onset of
mucosal damage, since the injury itself appears to stimulate endogenous expression so
markedly. The data from trefoil peptide transgenic animals are keenly awaited.
The number of trefoil peptides isolated is growing, and evidence was presented that
each region of the gut may have its own particular trefoil, as for the mucin genes. Indeed,
mucin genes and trefoil expression are linked geographically and, in lower animals, are
encoded by the same gene, which may explain their co-expression in mammals. Under
normal circumstances, mucin and trefoils are probably coordinately regulated, but perhaps
in disease states they may be uncoupled, or produced at a site remote from where they are
normally produced, giving rise to the "molecular metaplasia" proposed by Podolsky.
What are the stimuli from the damaged mucosa that promote cell division and repop-
ulation ofthe gland from the stem cell or its slightly more differentiated progeny? How is
this process regulated? Unlike the details of lineage determination and cell differentiation
in the bone marrow, these events are much less well understood in the gastric gland.
Similarly, we know next to nothing about how apoptosis is regulated in the gut. It will be
important to understand what switches on and off epithelial cell proliferation and apopto-
sis. For example, could gastric atrophy be due to excessive H. pylori-induced apoptosis?
Is cancer the result of too little apoptosis or too much proliferation?
Although this session mainly discussed the role of epithelial cells in mucosal repair,
the role of the non-epithelial cells should not be overlooked. Cells in the lamina propria
may be important not only in "filling the gap," but they may also be responsible for pro-
ducing some of the repair molecules. For example, hepatocyte growth factor is produced
by gastric fibroblasts in cell culture and appears to be an extremely potent mitogen and
motogen for epithelial cells [6]. Cell migration is typically accompanied by a reduction in
cell-cell interactions, as highlighted by Pignatelli, and mucosal repair must also involve
alterations in the interaction of cells with the extracellular matrix, typically mediated by
integrin molecules. In addition, mucosal repair is likely to be dependent upon the regula-
tion ofmatrix protein synthesis and its degradation by collagenases and metalloproteinas-
es. How this is regulated normally and how this regulation is altered when there is mucos-
al damage is not well understood. Finally, an important and relatively recently recognized
component ofthe repairprocess is angiogenesis. Interestingly, basic fibroblast growth fac-
tor, which is potently angiogenic as well as being mitogenic to a variety ofcell types, also
speeds epithelial restitution [7], and this peptide is currently being studied in therapeutic
trials [1]. It is noteworthy that sucralfate protects basic fibroblast growth factor from
destruction by gastric acid - yet another potential mechanism by which this drug may
heal ulcers.
Although most work presented in this session was on the molecular mechanisms of
mucosal repair, it is important not to neglect some important clues from studying how
mucosal repair occurs in vivo. Most chronic gastroduodenal ulceration in man is associated
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with chronic infection with H. pylori or non-steroidal anti inflammatory drug ingestion and
heals spontaneously when these precipitating factors are removed. Furthermore, ulcer heal-
ing can usually be achieved even in the presence of these factors by inhibiting acid secre-
tion. What does this tell us about the mucosal repairprocess? Perhaps the concomitant inhi-
bition of peptic activity which accompanies acid inhibition is important, suggested
Hirschowitz. Theproteolytic action ofpepsin onmatrix proteins will delay healingifmatrix
deposition is involved in mucosal repair. The fact that mucosal repair occurs, albeit slowly,
after H. pylon eradication alone and without acid inhibition, suggests that the organism
itself must inhibit mucosal repair. Dissecting the effect ofH. pylon from the effect of the
accompanying inflammatory process is not easy, which may be why this area has been so
far little studied. Epithelial cell function can be modulated by cytokines in many different
ways, but in vivo, chronic H. pylori infection appears to increase epithelial proliferation.
The effect ofH. pylori on restitution, matrix deposition and angiogenesis will be an inter-
esting area to explore.
In conclusion, we should remember that the therapeutic agents that we currently use
to heal ulcers were selected empirically, on the basis of symptom relief and healing effi-
cacy in vivo. If ultimately we wish to apply the knowledge derived from experimental
models and cell culture studies to enhance mucosal repair clinically, we will need to nar-
row the gap between the more basic sciences and clinical studies. This session discussed
some ofthe areas where this may be occurring andhighlighted others thatmay be promis-
ing to explore.
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